CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price objective increased by Raymond James from $17.00 to $33.00 in a research report report published on Thursday morning, Marketbeat.com reports. The brokerage currently has a strong-buy rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. BTIG Research increased their […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report)’s share price traded up 7.9% during trading on Monday after BTIG Research raised their price target on the stock from $22.00 to $24.00. BTIG Research currently has a buy rating on the stock. CymaBay Therapeutics traded as high as $17.55 and last traded at $17.53. 938,534 shares […]
Affinity Asset Advisors LLC trimmed its position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) by 5.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,083,118 shares of the biopharmaceutical company’s stock after selling 60,413 shares during the quarter. CymaBay Therapeutics […]
Logos Global Management LP trimmed its holdings in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) by 68.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 400,000 shares of the biopharmaceutical company’s stock after selling 850,000 shares during the period. Logos […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report)’s share price gapped up before the market opened on Friday after BTIG Research raised their price target on the stock from $22.00 to $24.00. The stock had previously closed at $15.01, but opened at $15.42. CymaBay Therapeutics shares last traded at $16.50, with a volume of 795,248 […]